EUVIMEDObjevte EUVIMED
Crossref

Childhood Interstitial Lung Disease in Metabolic Disorders: Prevalence, Genotypic and Clinical Characteristics, and Management Approaches: An Analysis of the Child‐Turkey Registry

Merve Selçuk Balcı iD, Fazılcan Zirek iD, Handan Kekeç, Melih Hangül, Gökçen Kartal Öztürk, Burcu Çapraz Yavuz iD, Gülay Bilgin, Beste Özsezen, Mina Hızal, Azer Kılıç Başkan, Ali Özdemir, Tuğba Ramaslı Gürsoy and 13 more

Pediatric Pulmonology · 2026-04 · 61 (4)

DOI: 10.1002/ppul.71603 ↗

At a glance

Journal article in Pediatric Pulmonology, published online on 2026-04-03. Written by Merve Selçuk Balcı and 24 co-authors. Institution: Department of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey. Major MEDLINE topics: Lung Diseases, Interstitial, Metabolic Diseases, Lysosomal Storage Diseases. 54 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Childhood interstitial lung disease (chILD) refers to a rare and heterogeneous group of disorders that can arise from genetic or acquired causes. Interstitial lung involvement due to metabolic diseases is a rare but significant condition among chILD cases.

Methods

This retrospective descriptive study analyzed data from the chILD‐Turkey registry, established in November 2021, including patients registered until August 2024.

Results

A total of 28 patients (3.9% of 706 children in the registry) were included, with lysosomal storage diseases (LSDs) accounting for 25 cases (89.3%) and Niemann‐Pick disease (NP) being the most common diagnosis ( n = 16, 57.1%), followed by Gaucher disease (GD) ( n = 7, 25.0%). The mortality rate during the 3‐year follow‐up was 10.7% (3/28). Computed tomography (CT) most commonly revealed interlobular septal thickening ( n = 17, 60.7%). No statistically significant differences in CT findings were observed between symptomatic and asymptomatic patients at the time of diagnosis. The most frequent variant in NP was c.416 T > C in SMPD1 ( n = 4, 25%), and in GD, c.1448 T > C was identified in four patients (57.1%). Eight patients (2 NP and 6 GD) received enzyme replacement therapy (ERT). No increase in respiratory support needs was observed under ERT, and one patient showed significant regression in CT findings during follow‐up. Conclusion chILD in metabolic disorders often progresses insidiously, resulting in delayed diagnosis. While management is mostly supportive, early ERT may improve or stabilize lung disease in selected cases. Further prospective studies are needed to clarify the impact of ERT and substrate reduction therapy (SRT) on long‐term pulmonary outcomes.

Subjects

MeSH terms (MEDLINE)

Lung Diseases, InterstitialMetabolic DiseasesLysosomal Storage DiseasesHumansFemaleRetrospective StudiesMaleRegistriesChildChild, PreschoolPrevalenceTurkeyInfantAdolescentTomography, X-Ray ComputedGenotypeNiemann-Pick DiseasesGaucher Disease

Author keywords

GaucherNiemann PickchILDlysosomal storage diseasesmetabolic disorders

Authors and institutions

  • Department of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Department of Pediatric Pulmonology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Department of Pediatric Pulmonology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Department of Pediatric Pulmonology, Cengiz Gökçek Children's Hospital, Gaziantep, Turkey.
  • Department of Pediatric Pulmonology, Ege University Faculty of Medicine, Izmir, Turkey.
  • Department of Pediatric Pulmonology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

ORCID profiles: Merve Selçuk Balcı, Fazılcan Zirek, Burcu Çapraz Yavuz, Nazan Çobanoğlu, Tuğba Şişmanlar Eyüboğlu

Cite

APA

Balcı, M. S., Zirek, F., Kekeç, H., Hangül, M., Öztürk, G. K., Yavuz, B. Ç., Bilgin, G., Özsezen, B., Hızal, M., Başkan, A. K., Özdemir, A., Gürsoy, T. R., Çobanoğlu, N., Eyüboğlu, T. Ş., Emiralioğlu, N., Ceylan, A. C., Oğuz, B., Orhan, D., Kılınç, A. A., …, & Gökdemir, Y. (2026). Childhood Interstitial Lung Disease in Metabolic Disorders: Prevalence, Genotypic and Clinical Characteristics, and Management Approaches: An Analysis of the Child‐Turkey Registry. Pediatric Pulmonology, 61(4). https://doi.org/10.1002/ppul.71603

Vancouver

Balcı MS, Zirek F, Kekeç H, Hangül M, Öztürk GK, Yavuz BÇ, et al. Childhood Interstitial Lung Disease in Metabolic Disorders: Prevalence, Genotypic and Clinical Characteristics, and Management Approaches: An Analysis of the Child‐Turkey Registry. Pediatric Pulmonology. 2026;61(4). doi:10.1002/ppul.71603

BibTeX
@article{Balc2026,
  author = {Balcı, Merve Selçuk and Zirek, Fazılcan and Kekeç, Handan and Hangül, Melih and Öztürk, Gökçen Kartal and Yavuz, Burcu Çapraz and Bilgin, Gülay and Özsezen, Beste and Hızal, Mina and Başkan, Azer Kılıç and Özdemir, Ali and Gürsoy, Tuğba Ramaslı and Çobanoğlu, Nazan and Eyüboğlu, Tuğba Şişmanlar and Emiralioğlu, Nagehan and Ceylan, Ahmet Cevdet and Oğuz, Berna and Orhan, Diclehan and Kılınç, Ayşe Ayzıt and Girit, Saniye and Pekcan, Sevgi and Cinel, Güzin and Yalçın, Ebru and Kiper, Nural and Gökdemir, Yasemin},
  title = {Childhood Interstitial Lung Disease in Metabolic Disorders: Prevalence, Genotypic and Clinical Characteristics, and Management Approaches: An Analysis of the Child‐Turkey Registry},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {4},
  doi = {10.1002/ppul.71603}
}
Start for free →